Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence and machine learning, has closed a registered direct offering that raised approximately $4.4 million in gross proceeds. The offering involved the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. In a concurrent private placement, the company also issued unregistered warrants to purchase up to 2,135,923 additional shares at an exercise price of $2.27 per share, which could generate up to approximately $4.85 million in additional gross proceeds if fully exercised.
The funds will support Lantern's continued development of its proprietary RADR platform, a technology that uses AI and machine learning to transform the development of cancer therapies. Lantern's clinical pipeline includes several promising candidates: LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (a cisplatin/ethacraplatin analog) currently being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Beyond its clinical pipeline, Lantern has recently launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, as it offers its AI capabilities to external researchers and organizations. The platform is designed to accelerate drug discovery and development by integrating advanced AI tools with domain expertise.
Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's focus on precision oncology aims to address significant unmet needs in cancer treatment, particularly for patients with limited therapeutic options. The completion of this offering provides Lantern with additional capital to advance its pipeline and expand its AI-driven initiatives, which could have broad implications for the biotech and pharmaceutical industries.
For investors and industry observers, the successful closing of the offering and the potential for additional proceeds from warrant exercises signal confidence in Lantern's strategic direction. The company's dual approach—combining a robust clinical pipeline with a commercial AI platform—positions it to potentially influence how cancer therapies are discovered and developed. As AI continues to permeate drug development, Lantern's progress could serve as a bellwether for the integration of machine learning in precision medicine.
